Last reviewed · How we verify
Recombinant human Growth Hormone
Recombinant human growth hormone binds to growth hormone receptors on target cells to stimulate growth, metabolism, and protein synthesis.
Recombinant human growth hormone binds to growth hormone receptors on target cells to stimulate growth, metabolism, and protein synthesis. Used for Growth hormone deficiency in children, Growth hormone deficiency in adults, Short stature due to growth hormone insufficiency.
At a glance
| Generic name | Recombinant human Growth Hormone |
|---|---|
| Also known as | Somatotropin, Genotropin(R), HGH, Saizen, r-hGH |
| Sponsor | University of Pennsylvania |
| Drug class | Growth hormone replacement therapy |
| Target | Growth hormone receptor (GHR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
This recombinant protein mimics endogenous human growth hormone by activating the growth hormone receptor, a transmembrane receptor that triggers intracellular signaling cascades. This leads to increased insulin-like growth factor 1 (IGF-1) production, enhanced protein synthesis, lipolysis, and linear growth in children. The drug restores physiological growth hormone levels in deficient patients.
Approved indications
- Growth hormone deficiency in children
- Growth hormone deficiency in adults
- Short stature due to growth hormone insufficiency
- Turner syndrome
- Chronic kidney disease-related growth failure
Common side effects
- Injection site reactions
- Headache
- Hyperglycemia
- Carpal tunnel syndrome
- Fluid retention
- Arthralgia
Key clinical trials
- Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) (PHASE4)
- Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR) (PHASE1, PHASE2)
- Growth Hormone Administration and the Human Immune System (PHASE1)
- Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer (PHASE3)
- The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature (PHASE3)
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
- A Study of GenSci134 in Children With Growth Hormone Deficiency (PGHD) (PHASE1, PHASE2)
- A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant human Growth Hormone CI brief — competitive landscape report
- Recombinant human Growth Hormone updates RSS · CI watch RSS
- University of Pennsylvania portfolio CI